


**AMENDMENTS TO THE CLAIMS**

Please amend the claims so that they read as follows:

1. (Currently Amended) A tetrahydro-naphthalene derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof:



wherein

n represents an integer of 0 to 6;

R<sub>1</sub> represents hydrogen or C<sub>1-6</sub> alkyl;

R<sub>2</sub> and R<sub>3</sub> together with the nitrogen atom to which they are attached, form a 3-8 membered saturated heterocyclic ring optionally interrupted by one or two atoms selected from the group consisting of oxygen, sulfur and nitrogen,

wherein said saturated heterocyclic ring has one or more substituents selected from the group consisting of halogen, benzyl, hydroxy, carboxy, amino, oxo, aminocarbonyl, C<sub>1-6</sub>

alkoxycarbonyl, and C<sub>1-6</sub> alkyl optionally substituted by hydroxy, carboxy, C<sub>1-6</sub> alkoxy, or C<sub>1-6</sub> alkoxy carbonyl,

or

R<sub>2</sub> represents C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, or C<sub>1-6</sub> alkyl substituted by amino, hydroxy, C<sub>1-6</sub> alkylamino, or di(C<sub>1-6</sub> alkyl)amino;

R<sub>3</sub> represents hydrogen, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, or C<sub>1-6</sub> alkyl optionally substituted by amino, hydroxy, C<sub>1-6</sub> alkylamino, or di(C<sub>1-6</sub> alkyl)amino; and

R<sub>4</sub> represents hydrogen, halogen, C<sub>1-6</sub> alkylthio, C<sub>1-6</sub> alkyl optionally substituted by mono-, di-, or tri-halogen, or C<sub>1-6</sub> alkoxy optionally substituted by mono-, di-, or tri-halogen.

2. (Currently Amended) The tetrahydro-naphthalene derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1,

wherein

n represents an integer of 0 or 1;

R<sub>1</sub> represents hydrogen;

R<sub>2</sub> and R<sub>3</sub> together with the nitrogen atom to which they are attached, form a 5-7 membered saturated heterocyclic ring optionally interrupted by one or two atoms selected from the group consisting of oxygen and nitrogen,

wherein said saturated heterocyclic ring has one or more substituents selected from the group consisting of benzyl, hydroxy, carboxy, oxo, aminocarbonyl, C<sub>1-6</sub> alkoxycarbonyl, and C<sub>1-6</sub> alkyl optionally substituted by hydroxy, C<sub>1-6</sub> alkoxy, or C<sub>1-6</sub> alkoxy carbonyl,

or

R<sub>2</sub> represents C<sub>1-6</sub> alkyl substituted by hydroxy, amino, C<sub>1-6</sub> alkylamino, or di(C<sub>1-6</sub> alkyl)amino;

R<sub>3</sub> represents hydrogen, C<sub>1-6</sub> alkyl optionally substituted by hydroxy, amino, C<sub>1-6</sub> alkylamino, or di(C<sub>1-6</sub> alkyl)amino; and

R<sub>4</sub> represents hydrogen, halogen, C<sub>1-6</sub> alkyl optionally substituted by mono-, di-, or tri-halogen, or C<sub>1-6</sub> alkoxy optionally substituted by mono-, di-, or tri-halogen.

3. (Currently Amended) The tetrahydro-naphthalene derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1, wherein

n represents an integer of 0 or 1;

R<sub>1</sub> represents hydrogen;

R<sub>2</sub> and R<sub>3</sub> together with the nitrogen atom to which they are attached, form a pyrrolidinyl optionally substituted by oxo, piperidine piperidinyl optionally substituted by hydroxy, carboxy, aminocarbonyl, C<sub>1-6</sub> alkoxycarbonyl, or C<sub>1-6</sub> alkyl optionally substituted by hydroxy, piperazinyl optionally substituted by benzyl, homopiperidine homopiperidinyl, or morpholinyl,

or

R<sub>2</sub> represents C<sub>1-6</sub> alkyl substituted by hydroxy, or di(C<sub>1-6</sub> alkyl)amino; R<sub>3</sub> represents hydrogen, or C<sub>1-6</sub> alkyl; and R<sub>4</sub> represents hydrogen, fluoro, chloro, bromo, C<sub>1-6</sub> alkyl optionally substituted by mono-, di-, or tri-halogen, or C<sub>1-6</sub> alkoxy.

4. (Currently Amended) ~~The A~~ tetrahydro-naphthalene derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1, wherein said tetrahydro-naphthalene derivative of the formula (I) is selected from the group consisting of:

N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-N'-[3-piperidin-1-yl-4-(trifluoromethyl)benzyl]urea;

N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-N'-[4-pyrrolidin-1-yl-3-(trifluoromethyl)benzyl]urea;

N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-N'-[3-pyrrolidin-1-yl-4-(trifluoromethyl)benzyl]urea;

N-[4-azepan-1-yl-3-(trifluoromethyl)benzyl]-N'-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)urea;

N-[3-azepan-1-yl-4-(trifluoromethyl)benzyl]-N'-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)urea;

N-(3-bromo-4-piperidin-1-ylbenzyl)-N'-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)urea;

N-[(7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]-N'-[3-pyrrolidin-1-yl-4-(trifluoromethyl)benzyl]urea;

N-[(7S)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]-N'-[3-pyrrolidin-1-yl-4-(trifluoromethyl)benzyl]urea;

N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-N'-[4-piperidin-1-yl-3-(trifluoromethyl)benzyl]urea;

ethyl 1-[5-[({[(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)amino]carbonyl}amino)-methyl]-2-(trifluoromethyl)phenyl]piperidine-4-carboxylate; and

N-[(7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]-N'-(3-morpholin-4-yl-4-(trifluoromethyl)benzyl]urea.

5. (Previously Presented) A pharmaceutical composition comprising a tetrahydro-naphthalene derivative of the formula (I), its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof as claimed in claim 1 in as an active ingredient, plus at least one pharmaceutically acceptable excipient.

6. (canceled)

7. (Previously Presented) The pharmaceutical composition as claimed in claim 5, wherein said tetrahydro-naphthalene derivative of the formula (I), its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof is a VR1 antagonist.

Claims 8 - 18. (canceled)

19. (Currently Amended) A process for controlling a urological disorder or disease in a human or animal comprising administering ~~a VR1-antagonist~~ an effective amount of at least one compound according to claim 1.

20. (Currently Amended) A process for controlling pain in a human or animal comprising administering ~~a VR1-antagonist~~ an effective amount of at least one compound according to claim 1.

21. (Currently Amended) A process for controlling an inflammatory disorder or disease in a human or animal comprising administering ~~a VR1-antagonist~~ an effective amount of at least one compound according to claim 1.

22. (Previously Presented) The process of claim 19 wherein said urological disorder is urge urinary incontinence or overactive bladder.

23. (Previously Presented) The process of claim 20 wherein said pain is chronic pain, neuropathic pain, postoperative pain, or rheumatoid arthritic pain.
24. (Previously Presented) The process of claim 21 wherein said inflammatory disorder or disease is asthma or COPD.
25. (Currently Amended) A process for controlling a disorder or disease related to pain associated with a disease or disorder comprising administering a VR1 antagonist(s) an effective amount of at least one compound according to claim 1.
26. (Currently Amended) The process of claim 25 wherein said disorder or disease related to pain is disorder or disease related to pain is neuralgia, a neuropathy, algesia, nerve injury, ischaemia, neurodegeneration, or stroke.